The challenge of systemic immunoglobulin light-chain amyloidosis (AL)

Subcellular Biochemistry

Volumn 65, Issue , 2012, Pages 609-642

  Palladini, Giovanni ^a   Comenzo, Raymond L ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

AL amyloidosis; Bortezomib; Cardiac amyloid; Free light chains; Immunoglobulin germline genes; Lenalidomide; Melphalan; Stem cell transplant; Thalidomide

Indexed keywords

AMYLOID; IMMUNOGLOBULIN LIGHT CHAIN;

AMYLOIDOSIS; ANIMAL; BLOOD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERGAMMAGLOBULINEMIA; PATHOLOGY; REVIEW;

AMYLOID; AMYLOIDOSIS; ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN LIGHT CHAINS;

EID: 84889658374     PISSN: 03060225     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-5416-4_22     Document Type: Article

References (177)

1. Abraham R, Geyer S, Price-Troska T, Allmer C, Kyle R, Gertz M, Fonseca R (2003a) Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 101:3801-3808
2. Abraham R, Katzmann J, Clark R, Bradwell A, Kyle R, Gertz M (2003b) Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 119:274-278
3. Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA (2003c) Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 119:274-278
4. Abraham R, Geyer S, Ramírez-Alvarado M, Price-Troska T, Gertz M, Fonseca R (2004) Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL). J Clin Immunol 24:340-353
5. Al-Zahrani GB, Bellavia D, Pellikka PA, Dispenzieri A, Hayman SR, Oh JK, Miyazaki C, Miller FA Jr (2009) Doppler myocardial imaging compared to standard 2-dimensional and doppler echocardiography for assessment of diastolic function in patients with systemic amyloidosis. J Am Soc Echocardiogr 22:290-298
6. Andersson K, Olofsson A, Nielsen EH, Svehag SE, Lundgren E (2002) Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem Biophys Res Commun 294:309-314
7. Ansari-Lari MA, Ali SZ (2004) Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test? Diagn Cytopathol 30:178-181
8. Aprile C, Marinone G, Saponaro R, Bonino C, Merlini G (1995) Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med 22:1393-1401
9. Bellavia D,Abraham TP, Pellikka PA, Al-Zahrani GB, Dispenzieri A, Oh JK, Bailey KR,Wood CM, Novo S, Miyazaki C, Miller FA Jr (2007) Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. J Am Soc Echocardiogr 20:1194-1202
10. Bergesio F, Ciciani AM, Santostefano M, Brugnano R, Manganaro M, Palladini G, Di Palma AM, Gallo M, Tosi PL, Salvadori M (2007) Renal involvement in systemic amyloidosis-an Italian retrospective study on epidemiological and clinical data at diagnosis. Nephrol Dial Transplant 22:1608-1618
11. Bernardi L, Passino C, Porta C, Anesi E, Palladini G, Merlini G (2002) Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension? Heart 88:615-621
12. Bochtler T, Hegenbart U, Cremer F, Heiss C, Benner A, Hose D, Moos M, Bila J, Bartram C, Ho A, Goldschmidt H, Jauch A, Schonland S (2008) Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood 111:4700-4705
13. Bochtler T, Hegenbart U, Heiss C, Benner A, Moos M, Seckinger A, Pschowski-Zuck S, Kirn D, Neben K, Bartram CR, Ho AD, Goldschmidt H, Hose D, Jauch A, Schonland SO (2011) Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). Blood 117:3809-3815
14. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468:93-97
15. BradwellA, Carr-Smith H, Mead G,Tang L, Showell P, Drayson M, DrewR (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47:673-680
16. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, Kumar S, Hayman S, Buadi F, Kyle RA, Greipp PR, Lust JA, Russell S, Rajkumar SV, Fonseca R, Dispenzieri A (2009) Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica 94:380-386
17. Caccialanza R, Palladini G, Klersy C, Cena H,Vagia C, Cameletti B, Russo P, Lavatelli F, Merlini G (2006) Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis. Am J Clin Nutr 83:350-354
18. Carroll JD, Gaasch WH, McAdam KP (1982) Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol 49:9-13
19. Child JS, Levisman JA, Abbasi AS, MacAlpin RN (1976) Echocardiographic manifestations of infiltrative cardiomyopathy. A report of seven cases due to amyloid. Chest 70:726-731
20. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H,AndreaNT, Sloan JM, FinnKT, Doros G, Blade J, SkinnerM (2011) Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 118:4346-4352
21. Cohen AD, Comenzo RL (2010) Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematol Am Soc Hematol Educ Program 2010:287-294
22. Cohen AD, Zhou P, Xiao Q, Fleisher M, Kalakonda N, Akhurst T, Chitale DA, Moscowitz C, Dhodapkar MV, Teruya-Feldstein J, Filippa D, Comenzo RL (2004) Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association. Br J Haematol 124:309-314
23. Cohen A, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa D, Riedel E, Kewalramani T, Stubblefield M, Fleisher M, Nimer S, Comenzo R (2007a) Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone ± thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 139:224-233
24. Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa DA, Riedel E, Kewalramani T, Stubblefield MD, Fleisher M, Nimer S, Comenzo RL (2007b) Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone ± thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 139:224-233
25. Comenzo RL (2009) How i treat amyloidosis. Blood 114:3147-3157
26. Comenzo R, GertzM (2002)Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99:4276-4282
27. Comenzo R, Vosburgh E, Simms R, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller D, Wright D, Falk R, Skinner M (1996) Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 88:2801-2806
28. Comenzo R, Michelle D, LeBlanc M,Wally J, ZhangY, Kica G, Karandish S, Arkin C, Wright D, Skinner M, McMannis J (1998a) Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and application. Transfusion 38:60-69
29. Comenzo R,Vosburgh E, Falk R, SanchorawalaV, Reisinger J, Dubrey S, Dember L, Berk J, Akpek G, LaValley M, O'hara C, Arkin C, Wright D, Skinner M (1998b) Dose-intensive melphalan with blood stem-cell support for the treatment ofAL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 91:3662-3670
30. Comenzo R,Wally J, Kica G, Murray J, EricssonT, Skinner M, ZhangY (1999) Clonal immunoglobulin light chain variable region germline gene use inAL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation. Br J Haematol 106:744-751
31. Comenzo R, ZhangY, Martinez C, Osman K, Herrera G (2001) The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood 98:714-720
32. Comenzo RL, Zhou P, Fleisher M, Clark B, Teruya-Feldstein J (2006) Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 107:3489-3491
33. Connors LH, Jiang Y, Budnik M, Théberge R, Prokaeva T, Bodi KL, Seldin DC, Costello CE, Skinner M (2007) Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kappa1 immunoglobulin light chains. Biochemistry 46:14259-14271
34. del PozoYauner L, Ortiz E, Sánchez R, Sánchez-López R, Güereca L, Murphy CL, Allen A,Wall JS, Fernández-Velasco DA, Solomon A, Becerril B (2008) Influence of the germline sequence on the thermodynamic stability and fibrillogenicity of human lambda 6 light chains. Proteins 72:684-692
35. Dember L, Sanchorawala V, Seldin D, Wright D, LaValley M, Berk J, Falk R, Skinner M (2001) Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease. Ann Intern Med 134:746-753
36. Dhodapkar M, Hussein M, Rasmussen E, SolomonA, Larson R, Crowley J, Barlogie B (2004) Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 104:3520-3526
37. Dietrich S, Schönland S, Benner A, Bochtler T, Kristen A, Beimler J, Hund E, Zorn M, Goldschmidt H, Ho A, Hegenbart U (2010a) Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 116:522-528
38. Dietrich S, Schonland SO, Benner A, Bochtler T, Kristen AV, Beimler J, Hund E, Zorn M, Goldschmidt H, Ho AD, Hegenbart U (2010b) Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 116:522-528
39. Dispenzieri A, Kyle R, Gertz M, Therneau T, MillerW, Chandrasekaran K, McConnell J, Burritt M, JaffeA (2003) Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 361:1787-1789
40. Dispenzieri A, Gertz M, Kyle R, Lacy M, Burritt M, Therneau T, Greipp P, Witzig T, Lust J, Rajkumar S, Fonseca R, Zeldenrust S, McGregor C, Jaffe A (2004a) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22:3751-3757
41. Dispenzieri A, Gertz M, Kyle R, Lacy M, Burritt M, Therneau T, McConnell J, Litzow M, Gastineau D, Tefferi A, Inwards D, Micallef I, Ansell S, Porrata L, Elliott M, Hogan W, Rajkumar S, Fonseca R, Greipp P,Witzig T, Lust J, Zeldenrust S, Snow D, Hayman S, McGregor C, Jaffe A (2004b) Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 104:1881-1887
42. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS (2004c) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22:3751-3757
43. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV,Abraham RS, Hayman SR,Kumar SK, Clark R, Kyle RA, Litzow MR, Inwards DJ, Ansell SM, Micallef IM, Porrata LF, Elliott MA, Johnston PB, Greipp PR,Witzig TE, Zeldenrust SR, Russell SJ, Gastineau D, Gertz MA (2006) Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 107:3378-3383
44. Dispenzieri A, Lacy M, Zeldenrust S, Hayman S, Kumar S, Geyer S, Lust J, Allred J, Witzig T, Rajkumar S, Greipp P, Russell S, Kabat B, GertzM (2007) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109:465-470
45. Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S, Buadi F, Zeldenrust S, Leung N, Detweiler-Short K, Lust JA, Russell SJ, Kyle RA, Gertz MA (2010a) Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol 85:757-759
46. Dispenzieri A, Gertz MA, Hayman SR, Buadi F, Kumar SK, Reeder C, Zeldenrust SR, Rajkumar SV, Detweiler-Short K, Lust JA,Witzig TE, Kyle RA, Greipp PR, Russell SJ, Dingli D, Allred JB, Laumann K, Thompson M, Fonseca R, Bergsagel L, Stewart K, Mikhael J, Roy V, Q LM (2010b) Pomalidomide and dexamethasone for previously treated al:a phase 2 study. Amyloid 17:87
47. Dubrey SW, Burke MM, Hawkins PN, Banner NR (2004) Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant 23:1142-1153
48. Eriksson P, Backman C, Bjerle P, Eriksson A, Holm S, Olofsson BO (1984) Non-invasive assessment of the presence and severity of cardiac amyloidosis. A study in familial amyloidosis with polyneuropathy by cross sectional echocardiography and technetium-99m pyrophosphate scintigraphy. Br Heart J 52:321-326
49. Falk RH (2011) Cardiac amyloidosis: a treatable disease, often overlooked. Circulation 124:1079- 1085
50. Fattori R, Rocchi G, Celletti F, Bertaccini P, Rapezzi C, Gavelli G (1998) Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. Am Heart J 136:824-830
51. Gertz MA, Kyle RA (2003) Amyloidosis with IgM monoclonal gammopathies. Semin Oncol 30:325-328
52. Gertz MA, Merlini G (2010) Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid 17:48-49
53. Gertz M, Kyle R, Greipp P (1989) The plasma cell labeling index: a valuable tool in primary systemic amyloidosis. Blood 74:1108-1111
54. Gertz M, Lacy M, Dispenzieri A, Ansell S, Elliott M, Gastineau D, Inwards D, Micallef I, Porrata L, Tefferi A, Litzow M (2004) Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 34:1025-1031
55. Gertz M, Comenzo R, Falk R, Fermand J, Hazenberg B, Hawkins P, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on amyloid and amyloidosis, tours, France, 18-22 April 2004. Am J Hematol 79:319-328
56. Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Hayman SR, Buadi F, Dingli D, Leung N, HoganWJ (2011) Trend toward improved day 100 and two-year survival following stem cell transplantation for AL: a comparison before and after 2006. Amyloid 18(Suppl 1):132-133
57. Ghio S, Perlini S, Palladini G, Marsan NA, Faggiano G,Vezzoli M, Klersy C, Campana C, Merlini G, Tavazzi L (2007) Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis. Eur J Heart Fail 9:808-813
58. Gillmore JD, Goodman HJ, Lachmann HJ, Offer M, Wechalekar AD, Joshi J, Pepys MB, Hawkins PN (2006) Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 107:1227-1229
59. Goldsmith YB, Liu J, Chou J, Hoffman J, Comenzo RL, Steingart RM (2009) Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring. Am J Cardiol 104:990-994
60. Haan J (1994) Amyloid and peripheral nervous system disease. Clin Neurol Neurosurg 96:332
61. Hachulla E, Maulin L, Deveaux M, Facon T, Blétry O,Vanhille P,Wechsler B, Godeau P, Levesque H, Hatron P, Huglo D, Devulder B, MarchandiseX (1996) Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: from diagnosis to prognosis.Am J Med 101:77-87
62. Han S, Chong V, Murray T, McDonagh T, Hunter J, Poon F, Gray H, Neilly J (2007) Preliminary experience of 99mTc-Aprotinin scintigraphy in amyloidosis. Eur J Haematol 79:494-500
63. Harris DL, King E, Ramsland PA, Edmundson AB (2000) Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes. J Mol Recognit 13:198-212
64. Harrison C, Mazzullo H, Ross F, Cheung K, Gerrard G, Harewood L, Mehta A, Lachmann H, Hawkins P, Orchard K (2002) Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. Br J Haematol 117:427-435
65. Hawkins P, Aprile C, Capri G, Viganò L, Munzone E, Gianni L, Pepys M, Merlini G (1998) Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. Eur J Nucl Med 25:701-708
66. Hayman S, Bailey R, Jalal S, Ahmann G, Dispenzieri A, Gertz M, Greipp P, Kyle R, Lacy M, Rajkumar S, Witzig T, Lust J, Fonseca R (2001) Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood 98:2266-2268
67. Hazenberg B, van Rijswijk M, Piers D, Lub-de Hooge M,Vellenga E, Haagsma E, Hawkins P, Jager P (2006) Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med 119:355.e315-324
68. Hoffman J Jhanwar S Comenzo R (2008) AL amyloidosis and progression to multiple myeloma with gain(1q). Br J Haematol 144:963-964
69. Hongo M, Urushibata K, Kai R, Takahashi W, Koizumi T, Uchikawa S, Imamura H, Kinoshita O, Owa M, Fujii T (2002) Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. Am Heart J 144:122-129
70. HunsteinW (2007) Epigallocathechin-3-gallate inALamyloidosis: a newtherapeutic option? Blood 110:2216
71. Iwakoshi NN, Lee AH, Vallabhajosyula P, Otipoby KL, Rajewsky K, Glimcher LH (2003) Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol 4:321-329
72. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette J, Ronco P, Quet F, Cogne M, Fermand J (2007) High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357:1083-1093
73. Jimenez-Zepeda V, Reeder C, Mikhael J, Dispenzieri A, Gertz M, Mayo A, Spong J, Fanning J, Bergsagel L, Stewart A, Fonseca R (2009) Cyclophosphamide, bortezomib and dexamethasone (CyBORD) induces rapid and complete responses in patients with amyloidosis not eligible for peripheral blood stem cell transplant. Blood 115:737-737
74. Kastritis E, Roussou M, Migkou M, Pamboukas K, Gavriatopoulou M, Gogos D, Liapis K, Michalis E, Delimpasi S, Psimenou E, Toumanidis S, Kontoyannis S, Terpos E, DimopoulosM (2009)A phase I/II study of lenalidomide (R) with low dose dexamethasone (d) and cyclophosphamide (C) for patients with primary systemic (AL) amyloidosis. Blood 115:177-178
75. Kastritis E, Wechalekar A, Dimopoulos M, Merlini G, Hawkins P, Perfetti V, Gillmore J, Palladini G (2010) Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 28:1031-1037
76. Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I, Marinaki S, Apostolou T, Nikitas N, Gkortzolidis G, Michalis E, Delimpasi S, Dimopoulos MA (2012) A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (rdc) in al amyloidosis. Blood 119: 5384-5390
77. Klein AL, Cohen GI (1992) Doppler echocardiographic assessment of constrictive pericarditis, cardiac amyloidosis, and cardiac tamponade. Cleve Clin J Med 59:278-290
78. Klein AL, Hatle LK, Taliercio CP, Taylor CL, Kyle RA, Bailey KR, Seward JB, Tajik AJ (1990) Serial DOPPLER echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 16:1135-1141
79. Koyama J, Ray-Sequin PA, Davidoff R, FalkRH (2002) Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis. Am J Cardiol 89:1067-1071
80. Koyama J, Ray-Sequin PA, Falk RH (2003) Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 107:2446-2452
81. Koyama J, Davidoff R, Falk RH (2004) Longitudinal myocardial velocity gradient derived from pulsed Doppler tissue imaging in AL amyloidosis: a sensitive indicator of systolic and diastolic dysfunction. J Am Soc Echocardiogr 17:36-44
82. Kpodonu J, Massad MG, Caines A, Geha AS (2005) Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant 24:1763-1765
83. KristenAV, Sack FU, Schonland SO, Hegenbart U, Helmke BM, Koch A, Schnabel PA, Rocken C, Hardt S, Remppis A, Goldschmidt H, Karck M, Ho AD, Katus HA, Dengler TJ (2009) Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. Eur J Heart Fail 11:1014-1020
84. Kristen A, Giannitsis E, Lehrke S, Hegenbart U, Konstandin M, Lindenmaier D, Merkle C, Hardt S, Schnabel P, Röcken C, Schonland S, Ho A, Dengler T, Katus H (2010) Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 116:2455-2461
85. Kumar S, Hayman S, Buadi F, Allred J, Laumann K, RoyV, Lacy M, Gertz M, Detweiler K, BirginA, Bergsagel L, Dingli D, Mikhael J, Reeder C, Stewart K, Zeldenrust S, Rajkumar V, Dispenzieri A (2009) A phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with light chain amyloidosis. Blood 115:1482-1482
86. Kumar SK, Hayman SR, Buadi FK, RoyV, Lacy MQ, Gertz MA,Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, Lust JA, Fonseca R, Russell SJ, Rajkumar SV, Dispenzieri A (2012) Lenalidomide, cyclophosphamide, and dexamethasone (crd) for light-chain amyloidosis: Long-term results from a phase 2 trial. Blood 119: 4860-4867
87. Kwong RY, Falk RH (2005) Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111:122-124
88. Kyle RA, Rajkumar SV (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23:3-9
89. Kyle R, Gertz M, Greipp P,Witzig T, Lust J, Lacy M, Therneau T (1997) Atrial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 336:1202-1207
90. Kyle R, Therneau T, Rajkumar S, Offord J, Larson D, Plevak M, Melton Lr (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564-569
91. Lachmann H, Gallimore R, Gillmore J, Carr-Smith H, Bradwell A, Pepys M, Hawkins P (2003) Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122:78-84
92. Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Kyle RA, Rajkumar SV, Edwards BS, Rodeheffer RJ, Frantz RP, Kushwaha SS, Clavell AL, Dearani JA, Sundt TM, Daly RC, McGregor CG, Gastineau DA, Litzow MR, Gertz MA (2008) Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. J Heart Lung Transplant 27:823-829
93. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL,Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448-6453
94. Landau H, Hassoun H, Bello C, Hoover E, Riedel ER, Nimer SD, ComenzoRL (2011) Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid 18(Suppl 1):130-131
95. Lebovic D, Hoffman J, Levine B, Hassoun H, Landau H, GoldsmithY, Maurer M, Steingart R, Cohen A, Comenzo R (2008a) Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 143:369-373
96. Lebovic D, Hoffman J, Levine BM, Hassoun H, Landau H, GoldsmithY, Maurer MS, Steingart RM, Cohen AD, Comenzo RL (2008b) Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 143:369-373
97. Liao R, Jain M, Teller P, Connors L, Ngoy S, Skinner M, Falk R, Apstein C (2001) Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 104:1594-1597
98. Lindqvist P, Olofsson BO, Backman C, Suhr O, Waldenstrom A (2006) Pulsed tissue Doppler and strain imaging discloses early signs of infiltrative cardiac disease: a study on patients with familial amyloidotic polyneuropathy. Eur J Echocardiogr 7:22-30
99. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ (2005) Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111:186-193
100. Maurer MS, Raina A, Hesdorffer C, Bijou R, Colombo P, Deng M, Drusin R, Haythe J, Horn E, Lee SH, Marboe C, NakaY, Schulman L, Scully B, Shapiro P, Prager K, Radhakrishnan J, Restaino S, Mancini D (2007) Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation 83:539-545
101. Mekinian A, Lions C, Leleu X, Duhamel A, Lamblin N, Coiteux V, De Groote P, Hatron PY, Facon T, Beregi JP, Hachulla E, Launay D, Group LAS (2010) Prognosis assessment of cardiac involvement in systemic AL amyloidosis by magnetic resonance imaging.Am J Med 123:864- 868
102. Mereles D, Buss SJ, Hardt SE, HunsteinW, Katus HA (2010) Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients withAL amyloidosis. Clin Res Cardiol 99:483-490
103. Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349:583-596
104. Merlini G,Westermark P (2004) The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 255:159-178
105. Merlini G, Stone M (2006) Dangerous small B-cell clones. Blood 108:2520-2530
106. Merlini G, Palladini G, Obici L, Anesi E, Saponaro R, Cannizzaro G, Aprile C (2001) Accuracy of 99mTc-Aprotinin scintigraphy for the detection of myocardial amyloidosis: Long-term followup of 78 patients. Amyloid 8:174-175
107. Merlini G, Seldin DC, Gertz MA (2011) Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 29:1924-1933
108. Mignot A, Varnous S, Redonnet M, Jaccard A, Epailly E, Vermes E, Boissonnat P, Gandjbakhch I, Herpin D, Touchard G, Bridoux F (2008) Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Arch Cardiovasc Dis 101:523-532
109. Moreau P, Jaccard A, Benboubker L, Royer B, Leleu X, Bridoux F, Salles G, Leblond V, Roussel M, Alakl M, Hermine O, Planche L, Harousseau JL, Fermand JP (2010) Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosedAL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood 116:4777-4782
110. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH (2005) Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 165:1425-1429
111. Oki T, Tanaka H, Yamada H, Tabata T, Oishi Y, Ishimoto T, Nagase N, Shinohara H, Sakabe K, Fukuda N (2004) Diagnosis of cardiac amyloidosis based on the myocardial velocity profile in the hypertrophied left ventricular wall. Am J Cardiol 93:864-869
112. Palladini G, Anesi E, Perfetti V, Obici L, Invernizzi R, Balduini C, Ascari E, Merlini G (2001a) A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 113:1044-1046
113. Palladini G, Malamani G, Cò F, Pistorio A, Recusani F, Anesi E, Garini P, Merlini G (2001b) Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol 24:1228- 1233
114. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, Obici L, Ascari E, d'Eril G, Moratti R, Merlini G (2003) Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107:2440-2445
115. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, Cavallero G, Rustichelli R, Virga G, Merlini G (2004) Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103:2936-2938
116. Palladini G, Kyle R, Larson D, Therneau T, Merlini G, Gertz M (2005a) Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis. Amyloid 12:120-126
117. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, Invernizzi R, Comotti B, Merlini G (2005b) The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 105:2949-2951
118. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, Obici L, Bradwell A, D'Eril G, Fogari R, Moratti R, Merlini G (2006a) Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107:3854-3858
119. Palladini G, Perfetti V, Merlini G (2006b) Therapy and management of systemic AL (primary) amyloidosis. Swiss Med Wkly 136:715-720
120. Palladini G, Russo P, Nuvolone M, Lavatelli F, PerfettiV, Obici L, Merlini G (2007) Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 110:787-788
121. Palladini G, Merlini G (2009) Current treatment ofAL amyloidosis. Haematologica 94:1044-1048
122. Palladini G, Russo P, Lavatelli F, Nuvolone M, Albertini R, Bosoni T, PerfettiV, Obici L, Perlini S, Moratti R, Merlini G (2009) Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol 88:347-350
123. Palladini G, Merlini G (2010) Transplantation vs. conventional-dose therapy for amyloidosis. Curr Opin Oncol 23:214-220
124. Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G, Perlini S, Albertini R, Russo P, Foli A, Bragotti LZ, Obici L, Moratti R, Melzi d'ErilGV, MerliniG (2010a) The combination of highsensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide typeB(NT-proBNP) after chemotherapy best predicts survival inALamyloidosis. Blood 116:3426-3430
125. Palladini G, DispenzieriA, GertzM,WechalekarA,Hawkins P, Schonland S,Hegenbart U, Comenzo R, Kastritis E, Dimopoulos M, Jaccard A, Klersy C, Merlini G (2010b) Validation of the criteria of response to treatment In AL amyloidosis. Blood 116:586-587
126. Palladini G, Barassi A, Perlini S, Milani P, Foli A, Russo P, Albertini R, Obici L, Lavatelli F, Sarais G, Casarini S, Moratti R, Melzi D'Eril GV, Merlini G (2011a) Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid 18:216-212
127. Palladini G, Russo P, Foli A, Milani P, Lavatelli F, Obici L, Nuvolone M, Brugnatelli S, Invernizzi R, Merlini G (2011b) Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol 91:89-92
128. Palladini G, Russo P, Milani P, Foli A, Lavatelli F, Nuvolone M, Perlini S, Merlini G (2012) A phase ii trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with al amyloidosis. Haematologica (in press)
129. Park M, Mueller P, Kyle R, Larson D, Plevak M, GertzM (2003) Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore) 82:291-298
130. Pepys M (2006) Amyloidosis. Annu Rev Med 57:223-241
131. Pepys MB, Herbert J, HutchinsonWL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417:254-259
132. Perfetti V, Bellotti V, Garini P, Zorzoli I, Rovati B, Marinone M, Ippoliti G, Merlini G (1994) AL amyloidosis. Characterization of amyloidogenic cells by anti-idiotypic monoclonal antibodies. Lab Invest 71:853-861
133. PerfettiV, Ubbiali P,Vignarelli MC, Diegoli M, Fasani R, Stoppini M, Lisa A, Mangione P, Obici L, Arbustini E, Merlini G (1998) Evidence that amyloidogenic light chains undergo antigen-driven selection. Blood 91:2948-2954
134. Perfetti V, Ubbiali P, Magni M, Colli Vignarelli M, Casarini S, Matteucci P, Gianni A, Merlini G (1999) Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis. Bone Marrow Transplant 23:323-327
135. Perfetti V, Coluccia A, Intini D, Malgeri U, Vignarelli M, Casarini S, Merlini G, Neri A (2001a) Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. Am J Pathol 158:1599-1603
136. Perfetti V, Vignarelli M, Casarini S, Ascari E, Merlini G (2001b) Biological features of the clone involved in primary amyloidosis (AL). Leukemia 15:195-202
137. Perfetti V, Casarini S, Palladini G, Vignarelli M, Klersy C, Diegoli M, Ascari E, Merlini G (2002a) Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood 100:948-953
138. PerfettiV, Casarini S, Palladini G,Vignarelli MC, Klersy C, Diegoli M,Ascari E, Merlini G (2002b) Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood 100:948-953
139. Perfetti V, Palladini G, Casarini S, Navazza V, Rognoni P, Obici L, Invernizzi R, Perlini S, Klersy C, Merlini G (2011) The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood 119:144-150
140. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46:1076-1084
141. Perugini E, Rapezzi C, Piva T, Leone O, Bacchi-Reggiani L, Riva L, Salvi F, Lovato L, Branzi A, Fattori R (2006) Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 92:343-349
142. Phipps JE, Kestler DP, Foster JS, Kennel SJ, Donnell R, Weiss DT, Solomon A, Wall JS (2010) Inhibition of pathologic immunoglobulin-free light chain production by small interfering RNA molecules. Exp Hematol 38:1006-1013
143. Pickford H, Swensen S, Utz J (1997) Thoracic cross-sectional imaging of amyloidosis. AJR Am J Roentgenol 168:351-355
144. Pinney JH, Lachmann HJ, Bansi L,Wechalekar AD, Gilbertson JA, Rowczenio D, Sattianayagam PT, Gibbs SD, Orlandi E,Wassef NL, Bradwell AR, Hawkins PN, Gillmore JD (2011) Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol 29:674-681
145. Reece D, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand J, Vescio R, Liu X, ElsayedY, Cakana A, Comenzo R (2009) Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 114:1489-1497
146. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Vescio RA, Liu K, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL (2011) Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 118: 865-873
147. Roig E, Almenar L, Gonzalez-Vilchez F, Rabago G, Delgado J, Gomez-Bueno M, Crespo-Leiro MG, Arizon JM, de la Fuente L, Manito N (2009) Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the spanish registry for heart transplantation. Am J Transplant 9:1414-1419
148. Ruberg FL, Appelbaum E, Davidoff R, Ozonoff A, Kissinger KV, Harrigan C, Skinner M, Manning WJ (2009) Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 103:544-549
149. Russo P, Palladini G, Foli A, Zenone Bragotti L, Milani P, Nuvolone M, Obici L, Perfetti V, Brugnatelli S, Invernizzi R, Merlini G (2011) Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients. Amyloid 18(Suppl 1):87-88
150. Sakono M, Zako T (2010) Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J 277:1348-1358
151. Sanchorawala V, Wright D, Quillen K, Finn K, Dember L, Berk J, Doros G, Fisher C, Skinner M, Seldin D (2007a) Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplant 40:557-562
152. Sanchorawala V, Wright D, Rosenzweig M, Finn K, Fennessey S, Zeldis J, Skinner M, Seldin D (2007b) Lenalidomide and dexamethasone in the treatment ofAL amyloidosis: results of a phase 2 trial. Blood 109:492-496
153. SanchorawalaV, Seldin DC, Berk JL, Sloan JM, Doros G, SkinnerM (2010). Oral cyclic melphalan and dexamethasone for patients with Al amyloidosis. Clin Lymphoma Myeloma Leuk 10:469- 472
154. Sanchorawala V, Quillen K, Sloan JM, Andrea NT, Seldin DC (2011) Bortezomib and high dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica 96:1890-1892
155. Sato H, Kuroda T, Tanabe N, Ajiro J, Wada Y, Murakami S, Sakatsume M, Nakano M, Gejyo F (2010) Cystatin C is a sensitive marker for detecting a reduced glomerular filtration rate when assessing chronic kidney disease in patients with rheumatoid arthritis and secondary amyloidosis. Scand J Rheumatol 39:33-37
156. Sattianayagam PT, Gibbs SD, Pinney JH, Wechalekar AD, Lachmann HJ, Whelan CJ, Gilbertson JA, Hawkins PN, Gillmore JD (2010) Solid organ transplantation in AL amyloidosis. Am J Transplant 10:2124-2131
157. Schonland S, Bochtler T, Ho A, Hegenbart U (2010) Efficacy and toxicity of dose-reduced bortezomib/ dexamethasone chemotherapy in patients with high risk cardiac light chain amyloidosis (Mayo Clinic stage III). Blood 116:817-818
158. Sethi S, Theis JD, Leung N, Dispenzieri A, Nasr SH, Fidler ME, Cornell LD, Gamez JD, Vrana JA, DoganA (2010) Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol 5:2180-2187
159. Siqueira-FilhoAG, Cunha CL, Tajik AJ, Seward JB, Schattenberg TT, Giuliani ER (1981) M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation 63:188- 196
160. Skinner M, Anderson J, Simms R, Falk R,Wang M, Libbey C, Jones L, CohenA (1996) Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 100:290-298
161. Skinner M, Sanchorawala V, Seldin D, Dember L, Falk R, Berk J, Anderson J, O'Hara C, Finn K, Libbey C, Wiesman J, Quillen K, Swan N, Wright D (2004) High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 140:85-93
162. SolomonA, Frangione B, Franklin E (1982) Bence Jones proteins and light chains of immunoglobulins. Preferential association of theVlambdaVI subgroup of human light chains with amyloidosis AL (lambda). J Clin Invest 70:453-460
163. Solomon A, Weiss D, Wall J (2003) Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother Radiopharm 18:853-860
164. Specter R, Sanchorawala V, Seldin DC, Shelton A, Fennessey S, Finn KT, Zeldis JB, Dember LM (2010) Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant 26:881-886
165. Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM, Thomas JD, Merlino JD (2009) Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography.Am J Cardiol 103:411-415
166. Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, Dispenzieri A, Oh JK, Bellavia D, Tajik AJ, Grogan M (2010) Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 3:155-164
167. Tapan U, Seldin DC, Finn KT, Fennessey S, Shelton A, Zeldis JB, SanchorawalaV (2010) Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood 116:5071-5072
168. ThomsonLE (2008) Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: diagnostic value of a typical pattern of late gadolinium enhancement. J Am Coll Cardiol 51: 1031-1032
169. Utz J, Swensen S, Gertz M (1996) Pulmonary amyloidosis. The mayo clinic experience from 1980 to 1993. Ann Intern Med 124:407-413
170. Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, Klingel K, Kandolf R, Sechtem U (2008) Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 51:1022-1030
171. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A (2009) Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 114:4957-4959
172. Wally J, Kica G, ZhangY, Ericsson T, Connors LH, Benson MD, Liepnieks JJ, Murray J, Skinner M, Comenzo RL (1999) Identification of a novel substitution in the constant region of a gene coding for an amyloidogenic kappa1 light chain. Biochim Biophys Acta 1454:49-56
173. Wechalekar A, Goodman H, Lachmann H, Offer M, Hawkins P, Gillmore J (2007) Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 109:457-464
174. Wechalekar A, Merlini G, Gillmore JD, Russo P, Lachmann H, Obici L, Hawkins PN, Palladini G (2008) Role of NT-ProBNP to assess the adequacy of treatment response in AL amyloidosis. Blood 112:596-597
175. Zhou P, Teruya-Feldstein J, Lu P, Fleisher M, Olshen A, Comenzo R (2008) Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan. Blood 111:549-557
176. Zhou P, Hoffman J, Landau H, Hassoun H, Iyer L, Comenzo RL (2012) Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin d1 in systemic light-chain amyloidosis. Clin Lymphoma Myeloma Leuk 12:49-58
177. Zonder J, Sanchorawala V, Snyder R, Matous J, Terebelo H, Janakiraman N, Mapara M, Lalo S, Tageja N, Webb C, Monsma D, Sellers C, Abrams J, Gasparetto C (2009) Melphalan and dexamethasone plus bortezomib induces hematologic and organ responses in AL-amyloidosis with tolerable neurotoxicity. Blood 115:310-311